Drug intelligence / Profile preview

AGT-105-T

Development stage: Preclinical
Lead developer: Addimmune
Modality: Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

AGT-105-T is an early discovery-stage autologous cell and gene therapy being developed by Addimmune (a spinoff of American Gene Technologies) for the treatment of HIV infection. Similar to other candidates in Addimmune's pipeline (such as AGT-103-T), the therapy is expected to utilize a lentiviral vector to genetically modify autologous CD4+ T cells ex vivo, rendering them resistant to HIV replication and entry (potentially by downregulating CCR5 and/or targeting viral genes via microRNAs) before reinfusing them into the patient to restore natural immune control of the virus.

Targets

CCR5 (C-C chemokine receptor type 5)CD4 (T lymphocyte surface antigen)

Beyond the preview

Go deeper on AGT-105-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGT-105-T.